<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.105119</article-id><article-id pub-id-type="publisher-id">ACM-35578</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200500000_15200114.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  唑来膦酸治疗原发性胆汁性胆管炎合并骨质疏松症的临床疗效研究
  Clinical Efficacy of Zoledronic Acid in the Treatment of Primary Biliary Cholangitis with Secondary Osteoporosis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>唐</surname><given-names>宁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>俪姗</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>斌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院风湿免疫科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>04</month><year>2020</year></pub-date><volume>10</volume><issue>05</issue><fpage>775</fpage><lpage>781</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：唑来膦酸作为第三代双膦酸盐，在临床上虽已广泛应用于绝经后骨质疏松的治疗，但在原发性胆汁性胆管炎(primary biliary cholangitis, PBC)继发骨质疏松症(osteoporosis, OP)患者中的治疗效果尚未得到评估。本研究旨在通过比较PBC继发骨质疏松症患者治疗前和治疗6个月后骨密度(bone minaral density, BMD)及骨代谢标志物的变化，探究唑来膦酸的治疗效果。方法：选择2012年10月至2019年10月期间于青岛大学附属医院风湿免疫科就诊的40例PBC合并继发性骨质疏松症者，应用5 mg (100 ml)唑来膦酸(密固达)进行静脉注射治疗一次，6个月后复查BMD、血清总Ι型胶原氨基酸延长肽(total N-terminal propeptide of type Ι procollagen, t-P1NP)、β胶原特殊序列(β collagen specific sequences, β-CTX)和25羟维生素D3 (25 hydroxy vitamin D3, 25-OH-VD
   <sub>3</sub>)，并与治疗前进行比较。结果：应用唑来膦酸治疗6个月后PBC继发骨质疏松患者的腰椎BMD和血清25-OH-VD
   <sub>3</sub>水平较治疗前明显升高，血清t-P1NP和β-CTX水平明显降低，而左股骨颈BMD无显著改善。结论：唑来膦酸能改善PBC继发骨质疏松症患者的腰椎BMD，降低血清骨转换标志物的水平，对PBC患者有显著的治疗效果。
    Objective: Zoledronic acid, as the third generation bisphosphonate, has been widely used in the clinical treatment of postmenopausal osteoporosis, but its efficacy has not been evaluated in patients with primary biliary cholangitis (PBC) secondary to osteoporosis (OP). The purpose of this study was to investigate the effect of zoledronic acid on bone density (BMD) and bone metabolism markers in patients with PBC secondary osteoporosis before and after 6 months of treatment. Methods: A total of 40 patients admitted to the Rheumatology Department of the Affiliated Hospital of Qingdao University from October 2012 to October 2019 were diagnosed as PBC complicated with OP and were treated by intravenous injection of 5 mg (100 ml) zoledronic acid (migoda). BMD, serum total N-terminal propeptide of type Ι procollagen (t-P1NP), beta collagen specific sequences (β-CTX) and 25-OH-VD
   <sub>3</sub> were reviewed 6 months after treatment and were compared with the results before treatment. Results: After 6 months of treatment with zoledronic acid, the lumbar BMD and serum 25-OH-VD
   <sub>3</sub> levels in patients with PBC were significantly higher than those before treatment, and the serum t-P1NP and β-CTX levels were significantly lower, while the left femoral neck BMD was not significantly improved. Conclusion: Zoledronic acid can improve lumbar BMD, reduce the level of serum bone conversion markers, and has a significant therapeutic effect on patients with PBC secondary osteoporosis. 
  
 
</p></abstract><kwd-group><kwd>原发性胆汁性胆管炎，继发性骨质疏松症，唑来膦酸，骨密度，骨代谢标志物, Primary Biliary Cholangitis</kwd><kwd> Osteoporosis</kwd><kwd> Zoledronic Acid</kwd><kwd> Bone Mineral Density</kwd><kwd> Bone Metabolic Marker</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>唑来膦酸治疗原发性胆汁性胆管炎合并骨质疏松症的临床疗效研究<sup> </sup></title><p>唐宁<sup>*</sup>，徐俪姗，刘斌<sup>#</sup></p><p>青岛大学附属医院风湿免疫科，山东 青岛</p><disp-formula id="hanspub.35578-formula36"><graphic xlink:href="//html.hanspub.org/file/14-1571300x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年4月23日；录用日期：2020年5月8日；发布日期：2020年5月15日</p><disp-formula id="hanspub.35578-formula37"><graphic xlink:href="//html.hanspub.org/file/14-1571300x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：唑来膦酸作为第三代双膦酸盐，在临床上虽已广泛应用于绝经后骨质疏松的治疗，但在原发性胆汁性胆管炎(primary biliary cholangitis, PBC)继发骨质疏松症(osteoporosis, OP)患者中的治疗效果尚未得到评估。本研究旨在通过比较PBC继发骨质疏松症患者治疗前和治疗6个月后骨密度(bone minaral density, BMD)及骨代谢标志物的变化，探究唑来膦酸的治疗效果。方法：选择2012年10月至2019年10月期间于青岛大学附属医院风湿免疫科就诊的40例PBC合并继发性骨质疏松症者，应用5 mg (100 ml)唑来膦酸(密固达)进行静脉注射治疗一次，6个月后复查BMD、血清总Ι型胶原氨基酸延长肽(total N-terminal propeptide of type Ι procollagen, t-P1NP)、β胶原特殊序列(β collagen specific sequences, β-CTX)和25羟维生素D3 (25 hydroxy vitamin D3, 25-OH-VD<sub>3</sub>)，并与治疗前进行比较。结果：应用唑来膦酸治疗6个月后PBC继发骨质疏松患者的腰椎BMD和血清25-OH-VD<sub>3</sub>水平较治疗前明显升高，血清t-P1NP和β-CTX水平明显降低，而左股骨颈BMD无显著改善。结论：唑来膦酸能改善PBC继发骨质疏松症患者的腰椎BMD，降低血清骨转换标志物的水平，对PBC患者有显著的治疗效果。</p><p>关键词 :原发性胆汁性胆管炎，继发性骨质疏松症，唑来膦酸，骨密度，骨代谢标志物</p><disp-formula id="hanspub.35578-formula38"><graphic xlink:href="//html.hanspub.org/file/14-1571300x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/14-1571300x8_hanspub.png" /> <img src="//html.hanspub.org/file/14-1571300x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>原发性胆汁性胆管炎(primary biliary cholangitis, PBC)，是一种自身免疫性、胆汁淤积性肝病 [<xref ref-type="bibr" rid="hanspub.35578-ref1">1</xref>]，主要影响中老年女性，且患病率呈逐年增长趋势 [<xref ref-type="bibr" rid="hanspub.35578-ref2">2</xref>]。乏力和皮肤瘙痒为最常见的首发症状，随着病情进展最终可导致肝硬化、肝衰竭等终末期肝病及其相关并发症 [<xref ref-type="bibr" rid="hanspub.35578-ref3">3</xref>]。骨质疏松症(osteoporosis, OP)是一种与骨量减少和骨组织微结构受损相关的全身性代谢性骨病 [<xref ref-type="bibr" rid="hanspub.35578-ref4">4</xref>]。世界卫生组织将OP定义为脊柱或股骨近端骨密度(BMD)较健康年轻受试者的峰值骨密度低至少2.5个标准差(SD) [<xref ref-type="bibr" rid="hanspub.35578-ref5">5</xref>]。根据发生原因不同，OP可分为原发性OP和继发性OP。本篇论文主要讨论继发性OP。</p><p>PBC患者OP的患病率明显升高，可达20%~52% [<xref ref-type="bibr" rid="hanspub.35578-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.35578-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.35578-ref8">8</xref>]。OP的患病率随着肝病的进展而增加，肝病晚期患者中骨密度正常的仅占20% [<xref ref-type="bibr" rid="hanspub.35578-ref6">6</xref>]。OP患者由于骨脆性增加，容易发生脆性骨折 [<xref ref-type="bibr" rid="hanspub.35578-ref9">9</xref>]。PBC患者的骨折发生率为10%~20%，晚期可达22% [<xref ref-type="bibr" rid="hanspub.35578-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.35578-ref11">11</xref>]。一旦发生脆性骨折将会严重影响患者的生活质量和身心健康，给家庭和社会带来巨大负担。因此，骨质疏松症作为PBC常见的并发症，越来越引起人们的重视。</p><p>目前尚无PBC继发OP的统一治疗方案，但双膦酸盐是临床上应用最广泛的药物。双膦酸盐能与骨质中的羟膦灰石特异性结合，抑制破骨细胞活性，从而减少骨质吸收 [<xref ref-type="bibr" rid="hanspub.35578-ref12">12</xref>]，但目前暂无评估其对PBC继发OP治疗效果的相关临床数据。本研究旨在通过比较PBC继发OP患者治疗前后BMD及骨代谢标志物的变化，探究唑来膦酸的治疗效果。</p></sec><sec id="s4"><title>2. 研究对象与方法</title><sec id="s4_1"><title>2.1. 研究对象</title><p>选取2012年10月至2019年10月于青岛大学附属医院就诊的PBC合并OP患者40例作为研究对象，收集临床资料，并于我院住院行唑来膦酸治疗。该研究已经过我院伦理委员会的审批。</p><sec id="s4_1_1"><title>2.1.1. 纳入标准</title><p>PBC患者均符合2018年美国肝病学会实践指导 [<xref ref-type="bibr" rid="hanspub.35578-ref13">13</xref>] 推荐的诊断标准：1) 血清生化检测提示胆汁淤积，以碱性磷酸酶(ALP)升高为主；2) AMA阳性或其他PBC特异性自身抗体，如抗sp100抗体、抗gp210抗体阳性；3) 肝组织学检查提示非化脓性破坏性胆管炎和小叶间胆管损伤。满足上述3项标准中的2项者即可诊断为PBC。</p><p>OP的诊断主要基于双能X线吸收检测法(DXA)测量的BMD结果以及有无脆性骨折。参照世界卫生组织(WHO)推荐的诊断标准 [<xref ref-type="bibr" rid="hanspub.35578-ref4">4</xref>]，对于绝经后女性，骨密度值(T-值)较同种族、同性别健康成年人的骨峰值降低等于或大于2.5个标准差诊断为骨质疏松，同时伴有脆性骨折者诊断为严重骨质疏松。</p></sec><sec id="s4_1_2"><title>2.1.2. 排除标准</title><p>1) 病例资料及临床相关辅助检查不完善者；</p><p>2) 患有血液系统疾病、内分泌系统疾病、恶性肿瘤、严重肝功能异常等影响骨代谢的疾病者；</p><p>3) 3个月内有糖皮质激素应用史者；</p><p>4) 严重肾功能损害者；</p><p>5) 妊娠和哺乳期妇女。</p></sec></sec><sec id="s4_2"><title>2.2. 研究方法</title><p>收集并记录40例PBC合并OP患者的骨代谢指标以及BMD检查结果。对于多次住院的患者，所有实验室检查均以首次就诊时的化验结果为准。治疗前嘱患者多饮水，并给予生理盐水水化，再将为5 mg (100 ml)的唑来膦酸以恒定速度静脉滴注一次，滴注时间不少于15分钟。对用药后出现发热、头痛、恶心、呕吐等不良反应的患者，给予对乙酰氨基酚缓释片、甲氧氯普胺等药物进行对症治疗。同时嘱患者每天补充钙剂和维生素D。治疗6个月后复查骨代谢标志物及骨密度，将治疗前后的结果进行自身前后对照并进行统计学分析。</p></sec><sec id="s4_3"><title>2.3. 检测指标</title><p>在应用唑来膦酸治疗前及治疗6个月后分别检测患者的血清总Ι型胶原氨基酸延长肽(total N-terminal propeptide of type Ι procollagen, t-P1NP)、β胶原特殊序列(β collagen specific sequences, β-CTX)、25羟维生素D3 (25-OH-VD<sub>3</sub>)，抽血前需空腹8小时以上，通常于次日晨间5:30~8:30进行静脉采血并立即送检。同时应用DXA测量腰椎和左侧股骨的骨密度。</p></sec><sec id="s4_4"><title>2.4. 统计学分析</title><p>使用SPSS 20.0软件对数据进行统计学分析。计量资料用均数&#177;标准差( x &#175; &#177; s )来表示。PBC患者治疗前后骨代谢标志物以及BMD变化的比较采用配对样本t检验。若P &lt; 0.05 则判定差异具有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 唑来膦酸治疗前后骨密度的变化</title><p>结果如表1所示，治疗6个月后40例PBC继发OP患者的腰椎BMD较治疗前明显升高，且差异具有统计学意义(P &lt; 0.05)；而左股骨颈BMD在治疗6个月后与治疗前相比，虽略有降低，但差异并没有统计学意义(P &gt; 0.05)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Changes of bone mineral density T value before and after zoledronic acid treatment (n = 40</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >腰椎骨密度</th><th align="center" valign="middle" >左股骨颈骨密度</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >−3.303 &#177; 0.543</td><td align="center" valign="middle" >−2.460 &#177; 0.693</td></tr><tr><td align="center" valign="middle" >治疗6个月后</td><td align="center" valign="middle" >−2.983 &#177; 0.379</td><td align="center" valign="middle" >−2.468 &#177; 0.620</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" >−6.106</td><td align="center" valign="middle" >0.231</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.819</td></tr></tbody></table></table-wrap><p>表1. 唑来膦酸治疗前后骨密度T值的变化(n = 40)</p></sec><sec id="s5_2"><title>3.2. 唑来膦酸治疗前后骨代谢指标的变化</title><p>结果如表2所示，治疗6个月后40例PBC继发OP患者的血清25羟维生素D3水平较治疗前有明显增加，且差异具有统计学意义(P &lt; 0.05)；与治疗前相比，治疗6个月后血清t-P1NP和β-CTX水平均明显下降，并且差异也具有统计学意义(P &lt; 0.05)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Changes of serum bone metabolic markers before and after treatment with zoledronic acid (n = 40</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >25-OH-VD<sub>3 </sub></th><th align="center" valign="middle" >β-CTX</th><th align="center" valign="middle" >t-P1NP</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >29.703 &#177; 9.513</td><td align="center" valign="middle" >0.370 &#177; 0.193</td><td align="center" valign="middle" >53.473 &#177; 17.105</td></tr><tr><td align="center" valign="middle" >治疗6个月后</td><td align="center" valign="middle" >32.428 &#177; 8.959</td><td align="center" valign="middle" >0.228 &#177; 0.120</td><td align="center" valign="middle" >29.220 &#177; 9.783</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" >−2.768</td><td align="center" valign="middle" >7.374</td><td align="center" valign="middle" >18.009</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.009</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表2. 唑来膦酸治疗前后血清骨代谢指标的变化(n = 40)</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>原发性胆汁性胆管炎(PBC)是一种慢性自身免疫性肝病，炎症过程主要发生在肝内胆管中，伴有大量的肝外并发症。既往认为PBC在我国是一种罕见病，但随着对本病的认识及临床诊断水平的提高，其发病率呈逐年增加的趋势，近年来发现PBC在我国并不少见。2010年我国一项关于PBC的区域流行病学调查发现，在8126例健康体检的成年群体中，其患病率为49.2/10万，其中40岁以上的女性人群中，患病率为155.8/10万 [<xref ref-type="bibr" rid="hanspub.35578-ref2">2</xref>]。</p><p>骨质疏松症是一种系统性骨骼疾病，与骨矿物质密度低和空间结构受损有关，增加脆性骨折的风险，尤其是在椎骨和股骨近端 [<xref ref-type="bibr" rid="hanspub.35578-ref14">14</xref>]。骨质疏松症是PBC常见的并发症 [<xref ref-type="bibr" rid="hanspub.35578-ref15">15</xref>]。既往研究显示，PBC继发OP的患病率约为14%~52% [<xref ref-type="bibr" rid="hanspub.35578-ref16">16</xref>]，在肝病晚期患病率可高达44% [<xref ref-type="bibr" rid="hanspub.35578-ref17">17</xref>]。OP的患者由于骨脆性增加，容易发生骨折。随着人口老龄化的加剧，OP及脆性骨折的发生率逐年升高，不仅给患者带来了精神和身体上的双重打击，也给家庭和社会带来了巨大的经济负担，严重影响了人类的寿命长短和生活质量。</p><p>利用DXA测定的BMD结果是目前诊断OP的金标准。但在临床上，由于OP起病较为隐匿，疾病早期常无明显症状，而且疾病的进展和BMD的变化也通常比较缓慢，所以OP的早期诊断和治疗存在一定挑战。而最近的研究发现骨代谢标志物的改变能帮助我们更早地发现骨代谢的异常，对OP患者的临床研究很有帮助 [<xref ref-type="bibr" rid="hanspub.35578-ref18">18</xref>]。在可用的生化标记中，专家推荐将t-P1NP和β-CTX分别作为骨形成和骨吸收的参考标记 [<xref ref-type="bibr" rid="hanspub.35578-ref19">19</xref>]。血液中t-P1NP的含量主要反映I型胶原的合成速率，是标志新骨形成的较为敏感的特异性指标。张萌萌等人的研究结果显示 [<xref ref-type="bibr" rid="hanspub.35578-ref20">20</xref>]，骨质疏松患者的血清t-PINP水平明显低于正常组。在OP等代谢性骨病中，I型胶原降解增高，相应的分解片段β-CTX在血液中的含量也随之增高，因此血清β-CTX是反映骨吸收的一个最有价值、最可靠的指标。25(OH)D<sub>3</sub>是人体维生素D的主要储存形式，是反映机体维生素D代谢的最好、最重要的指标，临床上一般通过监测血清 25(OH)D<sub>3</sub>的水平来反映血液维生素D3的水平。而体内维生素D3的缺乏是骨质疏松症的重要危险因素。</p><p>OP是PBC的常见并发症，导致该人群频繁发生骨折。目前尚无PBC继发骨质疏松症的统一治疗方案。双膦酸盐是临床上应用最广泛的抗骨吸收药物，它能与骨质中的羟膦灰石特异性结合，抑制破骨细胞活性，从而减少骨质吸收 [<xref ref-type="bibr" rid="hanspub.35578-ref12">12</xref>]。已有研究表明，阿仑膦酸钠、伊班膦酸钠能够防止骨质流失，从而使PBC患者的骨量增加、骨折风险降低 [<xref ref-type="bibr" rid="hanspub.35578-ref21">21</xref>]。</p><p>唑来膦酸作为第三代双膦酸盐，其对绝经后骨质疏松的治疗效果已得到证实。唑来膦酸是一种新型抗骨质疏松药物，有实验表明它是临床上药理活性最强的双膦酸盐类药物，其抗骨吸收的作用是一、二代双膦酸盐的一百倍以上。国内外的各项临床研究均显示唑来膦酸对于改善骨密度和降低骨折风险有显著疗效。一项国内试验结果显示，与每周口服一次70 mg阿仑膦酸钠相比，绝经后骨质疏松症女性每年5 mg唑来膦酸钠静脉内给药对改善骨密度和降低血清t-P1NP和β-CTX的疗效更高。并且与长期服用阿仑膦酸钠相比，长期应用唑来膦酸钠的中国女性发生不良事件的风险大大降低 [<xref ref-type="bibr" rid="hanspub.35578-ref22">22</xref>]。国外的一项随机对照试验显示，唑来膦酸盐可防止绝经后老年妇女的骨质流失近11年 [<xref ref-type="bibr" rid="hanspub.35578-ref23">23</xref>]。</p><p>关于唑来膦酸在PBC继发骨质疏松患者中的治疗效果，目前国内外并无相关研究数据及明确结论。为检测唑来膦酸的治疗效果，本研究比较了40例PBC继发骨质疏松患者治疗前和治疗半年后的骨密度以及骨代谢标志物的变化。结果显示，应用唑来膦酸5 mg静脉注射半年后，PBC合并骨质疏松患者的腰椎骨密度较治疗前明显改善，但股骨颈骨密度并无明显改善，说明唑来膦酸可使腰椎骨量增加。血清t-P1NP和β-CTX是与骨代谢相关的指标，唑来膦酸一方面可以抑制骨吸收，另一方面还有一定程度地促进骨矿化的作用。应用唑来膦酸治疗后血清t-P1NP和β-CTX均明显下降，说明骨转换减少，唑来膦酸对PBC继发骨质疏松患者有效，且治疗效果与绝经后骨质疏松女性相似。</p><p>随着对PBC这种疾病的认识以及我国诊疗水平的提高，PBC的患病率逐年上升，OP及脆性骨折的发生率也随之明显升高，除了给患者带来精神和身体上的双重打击外，也给患者家庭和整个社会带来了巨大的经济压力，严重影响了人类的寿命长短和生活质量。目前，唑来膦酸虽广泛应用于PBC继发OP的治疗，但国内外并无评估其有效性的临床研究。本研究通过对比40例PBC继发OP患者应用唑来膦酸治疗前后的的临床特征，证实了唑来膦酸的有效性，给未来的临床工作提供了宝贵的参考和依据。</p></sec><sec id="s7"><title>5. 结论</title><p>唑来膦酸能改善PBC继发OP患者的腰椎BMD，降低血清骨代谢标志物的水平，有效抑制破骨细胞的吸收活性，对PBC患者有显著的治疗效果。</p></sec><sec id="s8"><title>文章引用</title><p>唐 宁,徐俪姗,刘 斌. 唑来膦酸治疗原发性胆汁性胆管炎合并骨质疏松症的临床疗效研究Clinical Efficacy of Zoledronic Acid in the Treatment of Primary Biliary Cholangitis with Secondary Osteoporosis[J]. 临床医学进展, 2020, 10(05): 775-781. https://doi.org/10.12677/ACM.2020.105119</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.35578-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Selmi, C., Bowlus, C.L., Gershwin, M.E., et al. (2011) Primary Biliary Cirrhosis. The Lancet, 377, 1600-1609.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(10)61965-4</mixed-citation></ref><ref id="hanspub.35578-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L., Gershwin, M.E. and Wang, F.S. (2016) Primary Biliary Cholangitis in China. Current Opinion in Gastroenterology, 32, 195-203. &lt;br&gt;https://doi.org/10.1097/MOG.0000000000000257</mixed-citation></ref><ref id="hanspub.35578-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Purohit, T. and Cappell, M.S. (2015) Primary Biliary Cirrhosis: Pathophysiology, Clinical Presentation and Therapy. World Journal of Hepatology, 7, 926-941. &lt;br&gt;https://doi.org/10.4254/wjh.v7.i7.926</mixed-citation></ref><ref id="hanspub.35578-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">夏维波, 章振林, 林华, 等. 原发性骨质疏松症诊疗指南(2017) [J]. 中国骨质疏松杂志, 2019, 25(3): 281-309.</mixed-citation></ref><ref id="hanspub.35578-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">US OOTS (2004) Bone Health and Osteoporosis: A Report of the Surgeon General. Office of the Surgeon General (US), Rockville.</mixed-citation></ref><ref id="hanspub.35578-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Glass, L.M. and Su, G.L. (2016) Metabolic Bone Disease in Primary Biliary Cirrhosis. Gastroenterology Clinics of North America, 45, 333-343. &lt;br&gt;https://doi.org/10.1016/j.gtc.2016.02.009</mixed-citation></ref><ref id="hanspub.35578-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Guanabens, N., Cerda, D., Monegal, A., et al. (2010) Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients with Primary Biliary Cirrhosis. Gastroenterology, 138, 2348-2356.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2010.02.016</mixed-citation></ref><ref id="hanspub.35578-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Seki, A., Ikeda, F., Miyatake, H., et al. (2017) Risk of Secondary Osteoporosis Due to Lobular Cholestasis in Non-Cirrhotic Primary Biliary Cholangitis. Journal of Gastroenterology and Hepatology, 32, 1611-1616.  
&lt;br&gt;https://doi.org/10.1111/jgh.13746</mixed-citation></ref><ref id="hanspub.35578-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cosman, F., de Beur, S.J., LeBoff, M.S., et al. (2014) Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International, 25, 2359-2381. &lt;br&gt;https://doi.org/10.1007/s00198-014-2794-2</mixed-citation></ref><ref id="hanspub.35578-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Liang, J., Meng, W.D., Yang, J.M., et al. (2018) The Association between Liver Cirrhosis and Fracture Risk: A Systematic Review and Meta-Analysis. Clinical Endocrinology, 89, 408-413. &lt;br&gt;https://doi.org/10.1111/cen.13762</mixed-citation></ref><ref id="hanspub.35578-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Solaymani-Dodaran, M., Card, T.R., Aithal, G.P., et al. (2006) Fracture Risk in People with Primary Biliary Cirrhosis: A Population-Based Cohort Study. Gastroenterology, 131, 1752-1757. &lt;br&gt;https://doi.org/10.1053/j.gastro.2006.09.012</mixed-citation></ref><ref id="hanspub.35578-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Sanderson, J., Martyn-St, J.M., Stevens, J., et al. (2016) Clinical Effectiveness of Bisphosphonates for the Prevention of Fragility Fractures: A Systematic Review and Network Meta-Analysis. Bone, 89, 52-58.  
&lt;br&gt;https://doi.org/10.1016/j.bone.2016.05.013</mixed-citation></ref><ref id="hanspub.35578-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">王璐, 韩英. 《2018年美国肝病学会原发性胆汁性胆管炎实践指导》摘译[J]. 临床肝胆病杂志, 2018, 34(11): 2300-2304.</mixed-citation></ref><ref id="hanspub.35578-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Cooper, C., Campion, G. and Melton, L.R. (1992) Hip Fractures in the Elderly: A World-Wide Projection. Osteoporosis International, 2, 285-289. &lt;br&gt;https://doi.org/10.1007/BF01623184</mixed-citation></ref><ref id="hanspub.35578-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Guanabens, N., Pares, A., Ros, I., et al. (2005) Severity of Cholestasis and Advanced Histological Stage But Not Menopausal Status Are the Major Risk Factors for Osteoporosis in Primary Biliary Cirrhosis. Journal of Hepatology, 42, 573-577. &lt;br&gt;https://doi.org/10.1016/j.jhep.2004.11.035</mixed-citation></ref><ref id="hanspub.35578-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">(1994) Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Report of a WHO Study Group. World Health Organization Technical Report Series, 843, 1-129.</mixed-citation></ref><ref id="hanspub.35578-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Guichelaar, M.M., Kendall, R., Malinchoc, M., et al. (2006) Bone Mineral Density before and after OLT: Long-Term Follow-Up and Predictive Factors. Liver Transplantation, 12, 1390-1402. &lt;br&gt;https://doi.org/10.1002/lt.20874</mixed-citation></ref><ref id="hanspub.35578-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Garnero, P. (2017) The Utility of Biomarkers in Osteoporosis Management. Molecular Diagnosis &amp; Therapy, 21, 401-418. &lt;br&gt;https://doi.org/10.1007/s40291-017-0272-1</mixed-citation></ref><ref id="hanspub.35578-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">张萌萌, 张秀珍, 邓伟民, 等. 骨代谢生化指标临床应用专家共识(2019) [J]. 中国骨质疏松杂志, 2019, 25(10): 1357-1372.</mixed-citation></ref><ref id="hanspub.35578-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">张萌萌. 中国老年学学会骨质疏松委员会骨代谢生化指标临床应用专家共识[J]. 中国骨质疏松杂志, 2014, 20(11): 1263-1272.</mixed-citation></ref><ref id="hanspub.35578-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Zein, C.O., Jorgensen, R.A., Clarke, B., et al. (2005) Alendronate Improves Bone Mineral Density in Primary Biliary Cirrhosis: A Randomized Placebo-Controlled Trial. Hepatology, 42, 762-771. &lt;br&gt;https://doi.org/10.1002/hep.20866</mixed-citation></ref><ref id="hanspub.35578-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Tan, W., Sun, J., Zhou, L., et al. (2016) Randomized Trial Comparing Efficacies of Zoledronate and Alendronate for Improving Bone Mineral Density and Inhibiting Bone Remodelling in Women with Post-Menopausal Osteoporosis. Journal of Clinical Pharmacy and Therapeutics, 41, 519-523. &lt;br&gt;https://doi.org/10.1111/jcpt.12429</mixed-citation></ref><ref id="hanspub.35578-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Grey, A., Horne, A., Gamble, G., et al. (2020) Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial. The Journal of Clinical Endocrinology &amp; Metabolism, 105, e1641-e1647. &lt;br&gt;https://doi.org/10.1210/clinem/dgaa062</mixed-citation></ref></ref-list></back></article>